Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Molecular Models02:00

Molecular Models

43.5K
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
43.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's).

Chemistry & biodiversity·2026
Same author

Zanthoxylum armatum Essential Oil Attenuates MPP<sup>+</sup>-Induced Overexpression of Serine Palmitoyltransferase and Neurotoxicity in SH-SY5Y Cell Culture Model of Parkinson's Disease: Evidence From In Vitro and In Silico Studies.

Chemistry & biodiversity·2026
Same author

Protacs Targeting ERα in the Effective Management of Endocrinal Resistance Breast Cancer.

Archiv der Pharmazie·2025
Same author

Key therapeutic advances in aromatase inhibitors.

Future medicinal chemistry·2025
Same author

Animal models of polycystic ovary syndrome.

Systems biology in reproductive medicine·2025
Same author

Gaussian-based 3D-QSAR and Pharmacophore Mapping Studies of Indole Derivatives as Aromatase Inhibitors.

Anti-cancer agents in medicinal chemistry·2025

Related Experiment Video

Updated: Jan 13, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.4K

Molecular Simulation, Pharmacophore Mapping, and 3D QSAR Modeling on Chromene-Based SERDs.

Suresh Thareja1, Sanjana Bisht1

  • 1Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda, Punjab 151401, India.

Anti-Cancer Agents in Medicinal Chemistry
|January 9, 2026
PubMed
Summary

Researchers developed a novel chromene-based compound (Compound 18) that shows superior binding affinity to estrogen receptor alpha (ERα) compared to fulvestrant. This discovery offers potential for new oral selective estrogen receptor degraders (SERDs) to treat ER-positive breast cancer.

Keywords:
3D QSARBreast cancerSERDs.chromenecontour mapdockingestrogen receptor alphamolecular dynamics

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.1K
Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

6.9K

Related Experiment Videos

Last Updated: Jan 13, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.4K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.1K
Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

6.9K

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • Estrogen receptor alpha (ERα) is a key target for ER-positive breast cancer treatment.
  • Current selective estrogen receptor degraders (SERDs) face bioavailability limitations, and resistance can emerge due to ERα mutations.
  • Developing novel SERDs with improved efficacy and overcoming resistance mechanisms is crucial.

Purpose of the Study:

  • To elucidate the structure-activity relationship of chromene-based compounds as potential SERDs.
  • To design and predict the activity of novel ERα-targeting agents.
  • To identify compounds with enhanced binding affinity and therapeutic potential.

Main Methods:

  • Pharmacophore mapping and Gaussian field-based 3D Quantitative Structure-Activity Relationship (QSAR) modeling.
  • Molecular docking of the most active analogue into the ERα ligand binding domain (PDB ID: 6V8T).
  • Molecular dynamics simulations and MM/GBSA binding-free energy calculations.

Main Results:

  • A five-point pharmacophore hypothesis (HHHRR_1) was generated, guiding the development of a robust 3D QSAR model (q2=0.8, r2=0.94).
  • Compound 18 exhibited stable binding to ERα, with a calculated binding free energy (ΔGbind MM/GBSA) of -67.03 kcal/mol.
  • Compound 18 demonstrated superior binding affinity compared to fulvestrant (ΔGbind MM/GBSA = -64.76 kcal/mol), indicating enhanced target engagement.

Conclusions:

  • Integrated computational modeling successfully identified key molecular features for potent ERα degradation.
  • Compound 18, with its enhanced binding affinity, represents a promising lead for developing novel oral SERDs.
  • Optimizing the chromene scaffold can lead to new therapeutic agents for ER-positive breast cancer with improved potential.